10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

APOC2 Antibody (Center) Blocking Peptide
Synthetic peptide
Catalog # BP7796c

Specification

APOC2 Antibody (Center) Blocking Peptide - Product Information

Primary Accession P02655

APOC2 Antibody (Center) Blocking Peptide - Additional Information

Gene ID 344

Other Names
Apolipoprotein C-II, Apo-CII, ApoC-II, Apolipoprotein C2, Proapolipoprotein C-II, ProapoC-II, APOC2, APC2

Target/Specificity
The synthetic peptide sequence used to generate the antibody AP7796c was selected from the Center region of human APOC2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

APOC2 Antibody (Center) Blocking Peptide - Protein Information

Name APOC2

Synonyms APC2

Function
Component of chylomicrons, very low-density lipoproteins (VLDL), low-density lipoproteins (LDL), and high-density lipoproteins (HDL) in plasma. Plays an important role in lipoprotein metabolism as an activator of lipoprotein lipase. Both proapolipoprotein C-II and apolipoprotein C-II can activate lipoprotein lipase. In normolipidemic individuals, it is mainly distributed in the HDL, whereas in hypertriglyceridemic individuals, predominantly found in the VLDL and LDL.

Cellular Location
Secreted.

Tissue Location
Liver and intestine..

APOC2 Antibody (Center) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

APOC2 Antibody (Center) Blocking Peptide - Images

APOC2 Antibody (Center) Blocking Peptide - Background

APOC2 is secreted in plasma where it is a component of very low density lipoprotein. The protein activates the enzyme lipoprotein lipase, which hydrolyzes triglycerides and thus provides free fatty acids for cells. Mutations in the gene encodes this protein cause hyperlipoproteinemia type IB, characterized by hypertriglyceridemia, xanthomas, and increased risk of pancreatitis and early atherosclerosis.

APOC2 Antibody (Center) Blocking Peptide - References

Bahri,R., Lipids Health Dis 7, 46 (2008)Hegele,R.A., Dis. Markers 9 (2), 73-80 (1991)Bengtsson-Olivecrona,G., Eur. J. Biochem. 192 (2), 515-521 (1990)